Effects of polymers on the crystallinity of nanonized meloxicam during a co-grinding process

Csaba Mártha, Levente Kürti, Gabriella Farkas, Orsolya Jójárt-Laczkovich, B. Szalontai, Erik Glässer, M. Deli, P. Szabó-Révész

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Particle size reduction to the submicron region in a grinding process demands a high energy input. This grinding energy requirement can be reduced by means of a suitable additive, e.g. polymer, and performing a co-grinding process. Although these excipients promote attainment of the nanoparticle size range, they can also decrease the crystallinity of the active pharmaceutical ingredient. Different types of polymers have different abilities to amorphize the active material. To demonstrate the amorphization effects of different polymers, meloxicam (MX) as a model drug was subjected to co-grinding in the presence of one or other of four different polymers (PEG 6000, PEG 20,000, PVP C30 and PVP K25) and the products were investigated by XRPD, FT-IR and SEM. Although the PEG materials slightly melted and covered the MX particles during the grinding, they did not cause any changes in crystallinity. The PVP polymers softened and covered the MX particles, but drastically reduced the crystallinity of the drug. FT-IR revealed a weak secondary bonding between MX and the PVP polymer chain.

Original languageEnglish
Pages (from-to)2426-2432
Number of pages7
JournalEuropean Polymer Journal
Volume49
Issue number9
DOIs
Publication statusPublished - Sep 2013

Fingerprint

meloxicam
grinding
crystallinity
Polymers
polymers
Polyethylene glycols
Pharmaceutical Preparations
Amorphization
Excipients
drugs
energy requirements
Particle size
Nanoparticles
ingredients
Drug products
Scanning electron microscopy

Keywords

  • Co-grinding
  • Crystallinity
  • Meloxicam
  • Polyethylene glycol
  • Polyvinylpyrrolidone

ASJC Scopus subject areas

  • Polymers and Plastics
  • Physics and Astronomy(all)
  • Organic Chemistry

Cite this

Effects of polymers on the crystallinity of nanonized meloxicam during a co-grinding process. / Mártha, Csaba; Kürti, Levente; Farkas, Gabriella; Jójárt-Laczkovich, Orsolya; Szalontai, B.; Glässer, Erik; Deli, M.; Szabó-Révész, P.

In: European Polymer Journal, Vol. 49, No. 9, 09.2013, p. 2426-2432.

Research output: Contribution to journalArticle

Mártha, Csaba ; Kürti, Levente ; Farkas, Gabriella ; Jójárt-Laczkovich, Orsolya ; Szalontai, B. ; Glässer, Erik ; Deli, M. ; Szabó-Révész, P. / Effects of polymers on the crystallinity of nanonized meloxicam during a co-grinding process. In: European Polymer Journal. 2013 ; Vol. 49, No. 9. pp. 2426-2432.
@article{d5f2685d017d4131bddd49eb1603c1e1,
title = "Effects of polymers on the crystallinity of nanonized meloxicam during a co-grinding process",
abstract = "Particle size reduction to the submicron region in a grinding process demands a high energy input. This grinding energy requirement can be reduced by means of a suitable additive, e.g. polymer, and performing a co-grinding process. Although these excipients promote attainment of the nanoparticle size range, they can also decrease the crystallinity of the active pharmaceutical ingredient. Different types of polymers have different abilities to amorphize the active material. To demonstrate the amorphization effects of different polymers, meloxicam (MX) as a model drug was subjected to co-grinding in the presence of one or other of four different polymers (PEG 6000, PEG 20,000, PVP C30 and PVP K25) and the products were investigated by XRPD, FT-IR and SEM. Although the PEG materials slightly melted and covered the MX particles during the grinding, they did not cause any changes in crystallinity. The PVP polymers softened and covered the MX particles, but drastically reduced the crystallinity of the drug. FT-IR revealed a weak secondary bonding between MX and the PVP polymer chain.",
keywords = "Co-grinding, Crystallinity, Meloxicam, Polyethylene glycol, Polyvinylpyrrolidone",
author = "Csaba M{\'a}rtha and Levente K{\"u}rti and Gabriella Farkas and Orsolya J{\'o}j{\'a}rt-Laczkovich and B. Szalontai and Erik Gl{\"a}sser and M. Deli and P. Szab{\'o}-R{\'e}v{\'e}sz",
year = "2013",
month = "9",
doi = "10.1016/j.eurpolymj.2013.03.006",
language = "English",
volume = "49",
pages = "2426--2432",
journal = "European Polymer Journal",
issn = "0014-3057",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Effects of polymers on the crystallinity of nanonized meloxicam during a co-grinding process

AU - Mártha, Csaba

AU - Kürti, Levente

AU - Farkas, Gabriella

AU - Jójárt-Laczkovich, Orsolya

AU - Szalontai, B.

AU - Glässer, Erik

AU - Deli, M.

AU - Szabó-Révész, P.

PY - 2013/9

Y1 - 2013/9

N2 - Particle size reduction to the submicron region in a grinding process demands a high energy input. This grinding energy requirement can be reduced by means of a suitable additive, e.g. polymer, and performing a co-grinding process. Although these excipients promote attainment of the nanoparticle size range, they can also decrease the crystallinity of the active pharmaceutical ingredient. Different types of polymers have different abilities to amorphize the active material. To demonstrate the amorphization effects of different polymers, meloxicam (MX) as a model drug was subjected to co-grinding in the presence of one or other of four different polymers (PEG 6000, PEG 20,000, PVP C30 and PVP K25) and the products were investigated by XRPD, FT-IR and SEM. Although the PEG materials slightly melted and covered the MX particles during the grinding, they did not cause any changes in crystallinity. The PVP polymers softened and covered the MX particles, but drastically reduced the crystallinity of the drug. FT-IR revealed a weak secondary bonding between MX and the PVP polymer chain.

AB - Particle size reduction to the submicron region in a grinding process demands a high energy input. This grinding energy requirement can be reduced by means of a suitable additive, e.g. polymer, and performing a co-grinding process. Although these excipients promote attainment of the nanoparticle size range, they can also decrease the crystallinity of the active pharmaceutical ingredient. Different types of polymers have different abilities to amorphize the active material. To demonstrate the amorphization effects of different polymers, meloxicam (MX) as a model drug was subjected to co-grinding in the presence of one or other of four different polymers (PEG 6000, PEG 20,000, PVP C30 and PVP K25) and the products were investigated by XRPD, FT-IR and SEM. Although the PEG materials slightly melted and covered the MX particles during the grinding, they did not cause any changes in crystallinity. The PVP polymers softened and covered the MX particles, but drastically reduced the crystallinity of the drug. FT-IR revealed a weak secondary bonding between MX and the PVP polymer chain.

KW - Co-grinding

KW - Crystallinity

KW - Meloxicam

KW - Polyethylene glycol

KW - Polyvinylpyrrolidone

UR - http://www.scopus.com/inward/record.url?scp=84881367655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881367655&partnerID=8YFLogxK

U2 - 10.1016/j.eurpolymj.2013.03.006

DO - 10.1016/j.eurpolymj.2013.03.006

M3 - Article

AN - SCOPUS:84881367655

VL - 49

SP - 2426

EP - 2432

JO - European Polymer Journal

JF - European Polymer Journal

SN - 0014-3057

IS - 9

ER -